Related Experiment Video
Updated: Sep 15, 2025
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
Improved mRNA-based RSV vaccine with PreF forming enveloped virus-like particles
Pengdi Chai1, Yi Shi1, Xiaoyan Li2
1National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), NHC Key Laboratory for Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
New mRNA vaccines for respiratory syncytial virus (RSV) use enveloped virus-like particles (eVLPs) to create longer-lasting immunity and stronger antibody responses in mice, offering a promising new vaccine strategy.
Area of Science:
- Vaccinology
- Immunology
- Virology
Background:
- Respiratory syncytial virus (RSV) causes significant respiratory illness in vulnerable populations.
- Natural RSV infection and current vaccines provide insufficient long-term immune protection.
- Existing mRNA vaccines show limited durability in older adults.
Purpose of the Study:
- To develop a novel mRNA vaccine platform for respiratory syncytial virus (RSV) using antigen engineering.
- To enhance the immunogenicity and longevity of neutralizing antibodies against RSV.
- To investigate the underlying mechanisms of improved vaccine efficacy.
Main Methods:
- Engineered truncated RSV prefusion F (PreF) antigen by inserting an ESCRT/ALIX-binding region (EABR).
- Formulated engineered antigen into enveloped virus-like particles (eVLPs) for mRNA vaccine delivery.
- Assessed vaccine efficacy in murine models, measuring antibody responses, B cell populations, viral load, and pathology.
Main Results:
- PreF-EABR mRNA vaccines induced higher and more persistent neutralizing antibodies compared to conventional PreF mRNA vaccines.
- Enhanced germinal center B cell and memory B cell responses were observed with PreF-EABR mRNA vaccines.
- A lower dose of PreF-EABR mRNA vaccine (1 μg) achieved efficacy comparable to a higher dose of conventional PreF mRNA (2.5 μg).
Conclusions:
- The eVLPs technology with PreF-EABR antigen engineering significantly improves the longevity and potency of RSV mRNA vaccines.
- The enhanced immune response is linked to activated toll-like receptor and chemokine signaling pathways.
- This eVLP platform shows potential for developing durable vaccines against RSV and possibly other infectious diseases.
